3,063,365 Warrants of EBR Systems, Inc. are subject to a Lock-Up Agreement Ending on 24-JUN-2022.
June 23, 2022
Share
3,063,365 Warrants of EBR Systems, Inc. are subject to a Lock-Up Agreement Ending on 24-JUN-2022. These Warrants will be under lockup for 213 days starting from 23-NOV-2021 to 24-JUN-2022.
Details:
A total of 5,785,188 CDIs classified by ASX as restricted securities and to be held in escrow until November 24, 2023 being 24 months from the date of commencement of Quotation.
A total of 4,591,477 CDIs classified by ASX as restricted securities and to be held in escrow until June 24, 2022 being for 12 months from the date of issue.
A total of 550,181 CDIs classified by ASX as restricted securities and to be held in escrow until November 18, 2022 being for 12 months from the date of issue.
A total of 11,546,742 options exercisable at AUD 1.08 on or before November 23, 2031, classified by ASX as restricted securities and to be held in escrow until November 24, 2023, being 24 months from the date of commencement of Quotation.
A total of 1,104,030 warrants exercisable at AUD 0.41 and AUD 0.83 on or before August 26, 2029 and October 29, 2027 classified by ASX as restricted securities and to be held in escrow until November 24, 2023, being 24 months from the date of commencement of Quotation.
A total of 1,706,595 warrants exercisable at AUD 0.83 on or before February 12, 2031 classified by ASX as restricted securities and to be held in escrow until February 11, 2022 being 12 months from the date of issue.
A total of 3,063,365 warrants exercisable at AUD 0.83 on or before June 25, 2031 classified by ASX as restricted securities and to be held in escrow until June 24, 2022 being 12 months from the date of issue.
A total of 3,063,365 warrants exercisable at AUD 0.83 on or before October 4, 2031 classified by ASX as restricted securities and to be held in escrow until October 3, 2022 being 12 months from the date of issue.
EBR Systems, Inc. is engaged in the treatment for patients suffering from cardiac rhythm diseases by providing physiological stimulation through endocardiac pacing. The Company is engaged in developing and commercializing Wireless Stimulation Endocardially (WiSE), an implantable, cardiac pacing device able to provide stimulation to endocardial (inside the heart) heart tissue for the correction of heart rhythm conditions without requiring the use of leads. WiSE offers leadless solutions for LV Pacing, including cardiac resynchronization therapy (CRT) and conduction system pacing (CSP). The Company also offers CRT devices through the CRM subsegment under the brand names, including Visionist X4 CRT-P, Valitude X4 (CRT-P), Momentum CRT-D, Resonate X4 CRT-D, and Vigilant X4 CRT-D, among others. The Company operates various subsidiaries, which include EBR Systems (AUST) Pty. Ltd. and EBR Systems (UK) Limited, which establish clinical trials in Australia and the United Kingdom, respectively.
EBR SYSTEMS, INC. 
